What is the relative risk of continuing extended‑release bupropion 150 mg daily in a patient who suffered a transient ischemic attack or watershed stroke 14 days ago, with MRI pending?

Bupropion XL Should Be Discontinued in This Patient

Bupropion is contraindicated in patients with stroke, and continuing it 14 days post-TIA/watershed stroke poses unacceptable seizure risk that outweighs any potential benefit. The FDA drug label explicitly states that bupropion is "contraindicated in patients with seizure risks (ie, stroke, brain metastases)" 1, 2. This is not a relative contraindication—it is absolute.

Why This Matters for Your Patient

The Seizure Risk is Real and Dangerous

• Stroke lowers seizure threshold significantly, and bupropion further reduces it through its mechanism of action
• The combination creates a multiplicative risk, not just additive
• At 14 days post-event, your patient remains in the highest-risk period for both stroke recurrence and seizure development
• Even at the low dose of 150mg daily, the contraindication applies—there is no "safe" dose in stroke patients 2

The Timeline Works Against You

Your patient is still within the critical 2-week window where recurrent stroke risk remains elevated 3, 4, 3. Canadian Stroke Best Practice guidelines classify patients between 48 hours and 2 weeks post-TIA/stroke as "HIGH risk for recurrent stroke" 3. Adding a seizure-risk medication during this vulnerable period is contraindicated.

Clinical Decision Algorithm

Step 1: Discontinue bupropion immediately

• Do not wait for MRI results
• The contraindication applies whether this was TIA or watershed stroke
• Taper is not required at this dose if used for <2 weeks; if longer duration, taper over 1 week 5

Step 2: Address the underlying indication

• If prescribed for depression: Switch to an SSRI (sertraline, citalopram, escitalopram) which have no stroke contraindication
• If prescribed for smoking cessation:
  • First-line alternative: Varenicline (also has seizure concerns but less severe; still requires caution with brain metastases per guidelines 1)
  • Safer alternative: Nicotine replacement therapy (NRT) alone—patches plus short-acting NRT 1
  • Note: Limited safety data exist for varenicline and bupropion specifically in ischemic stroke patients 6

Step 3: Monitor for withdrawal effects

• Neuropsychiatric symptoms (irritability, depression, anxiety)
• These typically emerge within 24-72 hours if they occur
• Do not restart bupropion even if withdrawal symptoms develop

The Evidence Hierarchy

The FDA drug label 2 and NCCN smoking cessation guidelines 1 both explicitly contraindicate bupropion in stroke patients. This takes precedence over the limited research literature, which shows:

• A systematic review found "limited safety data" for bupropion in ischemic stroke 6
• One case report documented bupropion mimicking TIA symptoms 7
• No studies demonstrate safety of continuing bupropion post-stroke

The 2018 Canadian Stroke guidelines 3 emphasize aggressive risk factor modification in the first 2 weeks post-event but do not address bupropion specifically—because it should not be used.

Common Pitfalls to Avoid

1. Don't rationalize continuation based on low dose: The contraindication is not dose-dependent
2. Don't wait for "definitive" MRI diagnosis: The contraindication applies to both TIA and stroke
3. Don't assume the patient "tolerated it before": Stroke fundamentally changes seizure risk
4. Don't substitute with varenicline without careful consideration: While not absolutely contraindicated, varenicline carries warnings about seizure risk with brain metastases 1 and should be used cautiously

What to Tell Your Patient

"The medication you're taking for [depression/smoking cessation] is not safe to continue after your stroke/TIA. Stroke increases seizure risk, and this medication further increases that risk. We need to stop it now and switch to a safer alternative. This is based on FDA safety guidelines, not just my opinion."

The risk-benefit calculation is unambiguous: continuing bupropion offers no mortality or morbidity benefit that outweighs the concrete seizure risk in a post-stroke patient. Discontinue immediately.